Abstract: The present invention provides antibodies, or antigen-binding fragment thereof, which specifically bind to tumor necrosis factor (TNF)-like ligand (TL1A). The invention further provides a method of obtaining such antibodies and nucleic acids encoding the same. The invention further relates to compositions and therapeutic methods for use of these antibodies for the treatment and/or prevention of TL1A mediated diseases, disorders or conditions.

Abstract: The present invention provides antibodies, or antigen-binding fragment thereof, which specifically bind to tumor necrosis factor (TNF)-like ligand (TL1A). The invention further provides a method of obtaining such antibodies and nucleic acids encoding the same. The invention further relates to compositions and therapeutic methods for use of these antibodies for the treatment and/or prevention of TL1A mediated diseases, disorders or conditions.

Abstract: The present invention provides antibodies, or antigen-binding fragment thereof, which specifically bind to tumor necrosis factor (TNF)-like ligand 1A(TL1A) The invention further provides a method of obtaining such antibodies and nucleic acids encoding the same. The invention further relates to compositions and therapeutic methods for use of these antibodies for the treatment and/or prevention of TL1A mediated diseases, disorders or conditions.

Abstract: The invention provides a dual VEGF/PDGF antagonist comprising a VEGF antagonist linked to a PDGF antagonist. The VEGF antagonist is an antibody to a VEGF or VEGFR or is a VEGFR extracellular trap segment (i.e., a segment from the extracellular region of one or more VEGFR receptors that inhibits binding of at least one VEGFR to at least one VEGF). The PDGF antagonist is an antibody to a PDGF or PDGFR or is a PDGFR extracellular trap segment (i.e., segment from the extracellular region of one or more PDGFRs, which inhibits binding of at least one PDGFR and at least one PDGF). The dual antagonist is preferably conjugated to a half-life extending moiety, such as a HEMA-PC polymer. The dual antagonist is particularly useful for treating wet aged related macular degeneration.

Abstract: The invention provides a dual VEGF/PDGF antagonist comprising a VEGF antagonist linked to a PDGF antagonist. The VEGF antagonist is an antibody to a VEGF or VEGFR or is a VEGFR extracellular trap segment (i.e., a segment from the extracellular region of one or more VEGFR receptors that inhibits binding of at least one VEGFR to at least one VEGF). The PDGF antagonist is an antibody to a PDGF or PDGFR or is a PDGFR extracellular trap segment (i.e., segment from the extracellular region of one or more PDGFRs, which inhibits binding of at least one PDGFR and at least one PDGF). The dual antagonist is preferably conjugated to a half-life extending moiety, such as a HEMA-PC polymer. The dual antagonist is particularly useful for treating wet aged related macular degeneration.

Abstract: The present invention provides antibodies, or antigen-binding fragment thereof, which specifically bind to TL1A. The invention further provides a method of obtaining such antibodies and nucleic acids encoding the same. The invention further relates to compositions and therapeutic methods for use of these antibodies for the treatment and/or prevention of TL1A mediated diseases, disorders or conditions.

Abstract: The present invention relates to monomeric polypeptides comprising an engineered monomeric antibody fragment (e.g., monomeric Fc-containing polypeptides) wherein the monomeric Fc comprises one or more engineered N-linked glycosylation sites in the CH3-CH3 dimerization interface. Methods for producing such engineered monomeric antibody fragments and their use in diagnostics and therapeutics are also provided.

Abstract: The present invention provides antibodies, or antigen-binding fragment thereof, which specifically bind to TL1A. The invention further provides a method of obtaining such antibodies and nucleic acids encoding the same. The invention further relates to compositions and therapeutic methods for use of these antibodies for the treatment and/or prevention of TL1A mediated diseases, disorders or conditions.

Abstract: The invention provides a dual VEGF/PDGF antagonist comprising a VEGF antagonist linked to a PDGF antagonist. The VEGF antagonist is an antibody to a VEGF or VEGFR or is a VEGFR extracellular trap segment (i.e., a segment from the extracellular region of one or more VEGFR receptors that inhibits binding of at least one VEGFR to at least one VEGF). The PDGF antagonist is an antibody to a PDGF or PDGFR or is a PDGFR extracellular trap segment (i.e., segment from the extracellular region of one or more PDGFRs, which inhibits binding of at least one PDGFR and at least one PDGF). The dual antagonist is preferably conjugated to a half-life extending moiety, such as a HEMA-PC polymer. The dual antagonist is particularly useful for treating wet aged related macular degeneration.

Abstract: The present invention provides antibodies, or antigen-binding fragment thereof, which specifically bind to tumor necrosis factor-like ligand 1A (TL1A). The invention further provides a method of obtaining such antibodies and nucleic acids encoding the same. The invention further relates to compositions and therapeutic methods for use of these antibodies for the treatment and/or prevention of TL1A mediated diseases, disorders or conditions.

Abstract: The invention provides a dual VEGF/PDGF antagonist comprising a VEGF antagonist linked to a PDGF antagonist. The VEGF antagonist is an antibody to a VEGF or VEGFR or is a VEGFR extracellular trap segment (i.e., a segment from the extracellular region of one or more VEGFR receptors that inhibits binding of at least one VEGFR to at least one VEGF). The PDGF antagonist is an antibody to a PDGF or PDGFR or is a PDGFR extracellular trap segment (i.e., segment from the extracellular region of one or more PDGFRs, which inhibits binding of at least one PDGFR and at least one PDGF). The dual antagonist is preferably conjugated to a half-life extending moiety, such as a HEMA-PC polymer. The dual antagonist is particularly useful for treating wet aged related macular degeneration.

Abstract: The present invention relates to monomeric polypeptides comprising an engineered monomeric antibody fragment (e.g., monomeric Fc-containing polypeptides) wherein the monomeric Fc comprises one or more engineered N-linked glycosylation sites in the CH3-CH3 dimerization interface. Methods for producing such engineered monomeric antibody fragments and their use in diagnostics and therapeutics are also provided.

Abstract: The present invention provides antibodies, or antigen-binding fragment thereof, which specifically bind to TL1A. The invention further provides a method of obtaining such antibodies and nucleic acids encoding the same. The invention further relates to compositions and therapeutic methods for use of these antibodies for the treatment and/or prevention of TL1A mediated diseases, disorders or conditions.

Abstract: The present invention provides a FGF21 molecule covalently attached to the combining site of an antibody via a linker, wherein the linker is covalently attached to the side chain of a linking residue within FGF21. Various uses of the compounds are provided, including methods to prevent or treat diabetes or diabetes-related conditions.

Abstract: The present invention provides a FGF21 molecule covalently attached to the combining site of an antibody via a linker, wherein the linker is covalently attached to the side chain of a linking residue within FGF21. Various uses of the compounds are provided, including methods to prevent or treat diabetes or diabetes-related conditions.

Abstract: An exhaust gas cooling system for an engine includes an exhaust gas conduit having an inner tube defining an exhaust gas passage and an exhaust coupler surrounding the inner tube and defining a cooling water passage together with the inner tube therebetween, and a water-lock coupled with a downstream end of the exhaust gas conduit through an exhaust gas conduit coupling section which extends from an upstream end of the water-lock. The exhaust gas conduit coupling section and the exhaust coupler are coupled with each other and the inner tube extends into the interior of the water-lock. A downstream end part of the inner tube can be formed to be a wide portion having a bell mouth configuration. A diameter of the downstream end part becomes larger as a portion thereof exists closer to the end of the downstream end part. The exhaust gas cooling system for the engine can be provided for a water vehicle.

Abstract: An exhaust gas cooling system for an engine includes an exhaust gas conduit having an inner tube defining an exhaust gas passage and an exhaust coupler surrounding the inner tube and defining a cooling water passage together with the inner tube therebetween, and a water-lock coupled with a downstream end of the exhaust gas conduit through an exhaust gas conduit coupling section which extends from an upstream end of the water-lock. The exhaust gas conduit coupling section and the exhaust coupler are coupled with each other and the inner tube extends into the interior of the water-lock. A downstream end part of the inner tube can be formed to be a wide portion having a bell mouth configuration. A diameter of the downstream end part becomes larger as a portion thereof exists closer to the end of the downstream end part. The exhaust gas cooling system for the engine can be provided for a water vehicle.

Abstract: A cooling system particularly suited for use in a small watercraft, which supplies coolant to, and evacuates coolant from, an engine of the watercraft. The engine includes an engine body defining at least one water jacket therein. An engine coolant supply passage desirably routes the coolant into thermal communication with a portion of an exhaust system, such as an exhaust manifold, before supplying the coolant to the water jacket of the engine. When the engine is shut off, coolant is permitted to drain from the water jacket through a drain passage. The drain passage is connected to the coolant supply passage at a position upstream from the exhaust system such that coolant draining from the engine travels in a reverse direction through the supply passage and is drained from the watercraft cooling system.

Abstract: An induction system for a watercraft is configured to guide air into an engine disposed within the watercraft for combustion therein. The induction system includes an inlet assembly. The inlet assembly includes various constructions for enhancing water preclusive effects.

Abstract: An induction system for a watercraft includes a first intake air chamber communicating with at least one combustion chamber of an engine of the watercraft, and a second intake air chamber communicating with the first intake air chamber via a conduit. The second intake air chamber may be arranged in various orientations and/or with various other features which improve attenuation of induction noises and/or the preclusion of water from entering the engine through the induction system.